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Glioblastoma initiating cells and therapeutic
targetingCENPA is a centromere-associated variant of histone H3 implicated in numerous malignancies. However, the
role of this protein in glioblastoma (GBM) has not been demonstrated. GBM is one of the most aggressive
human cancers. GBM initiating cells (GICs), contained within these tumors are deemed to convey
characteristics such as invasiveness and resistance to therapy. Therefore, there is a strong rationale for
targeting these cells. We investigated the expression of CENPA and other centromeric proteins (CENPs) in
GICs, GBM and variety of other cell types and tissues. Bioinformatics analysis identiﬁed the gene signature:
high_CENP(AEFNM)/low_CENP(BCTQ) whose expression correlated with signiﬁcantly worse GBM patient
survival.
Knockdown of CENPA reduced sphere forming ability, proliferation and cell viability of GICs. We also
detected signiﬁcant reduction in the expression of stemness marker SOX2 and the proliferation marker
Ki67. These results indicate that CENPAmight represent a promising therapeutic target for GBM treatment.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glioblastoma (GBM) is one of the most malignant human cancers
with dismal prognosis. Despite multimodal therapy and inclusion of
temozolomide, median survival remains unchanged (Helseth et al.,
2010; Ronning et al., 2012). Glioblastoma initiating cells (GICs), a cell
population with stem cell properties (also referred to as glioblastoma
stem cells, GSCs) harbored with within these tumors are deemed
important for retaining GBM properties (Galli et al., 2004; Singh et al.,
2003; Vescovi et al., 2006). GICs are invasive (Cheng et al., 2011;Molina
et al., 2010), promote tumor angiogenesis (Folkins et al., 2009; Das and
Marsden, 2013; Bao et al., 2006) and are resistant to irradiation and
chemotherapy (Bao et al., 2006; Chen et al., 2012; Liu et al., 2006).
Consequently, there is a strong rationale for targeting these cells.
We have compared gene expression in GICs to that in neural stem
cells (NSCs) from the adult human brain, and identiﬁed genes and
biochemical pathways typically up-regulated in GICs (Sandberg et al.,
2013; Stangeland et al., 2015). Although these two cell types share
common stem- and lineage-related markers, GICs show a more
heterogeneous gene expression and a number of pathways such as
Wnt signaling, cell cycle and p53 signaling are dysregulated in GICsB. Stangeland).
habetically.
open access article under the CC B(Sandberg et al., 2013). This analysis also revealed a 30-gene signature
highly up-regulated in GICs that had an impact on survival of glioma
patients (Sandberg et al., 2013). Recently we identiﬁed a
glioblastoma-speciﬁc coexpression module that consisted of PBK/TOPK,
CENPA, KIF15, DEPDC1, CDC6, DLG7/DLGAP5/HURP, KIF18A, EZH2, HMMR/
RHAMM/CD168, NOL4, MPP6, MDM1, RAPGEF4, RHBDD1, FNDC3B, FILIP1L,
MCC, ATXN7L4/ATXN7L1, P2RY5/LPAR6 and FAM118A (Stangeland et al.,
2015). All nine genes in the module were highly up-regulated in GBM
and were predominantly involved in cell division, cell-cycle and
proliferation (Stangeland et al., 2015). The cumulative increased
expression of this nine-gene module correlated negatively with survival
of GBM patients thus suggesting that they might represent potential
therapeutic targets (Stangeland et al., 2015). Two of the genes KIF15 and
KIF18Awere involved inmitotic kinesis (Stangeland et al., 2015). KIF15 is
required for spindle function and has recently been targeted by using
quinazolinedione and phthalimide (Mcdonald et al., 2004). KIF18A is
involved in chromosome congression and a speciﬁc inhibitor BTB1 that
targets this gene was recently discovered (Catarinella et al., 2009).
Knockdown of a further three genes: HMMR (Tilghman et al., 2014),
EZH2 (Suva et al., 2009) and PBK (Joel et al., 2015) resulted in severe
reduction of tumorigenic features of GICs.
One of the nine genes, encoding a centromeric protein ‘A’ (CENPA),
was highly up-regulated in GICs both at RNA and protein levels
(Stangeland et al., 2015). CENPA, is a variant of histone H3 (Sullivan et
al., 1994) that was ﬁrstly identiﬁed in scleroderma patients (Moroi etY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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identiﬁed in organisms from yeast to human, where they serve as
markers of centromeric chromatin identity (Verdaasdonk and Bloom,
2011). During cell division the centromere recruits the kinetochore that
additionally attaches to the spindle. CENPA secures proper kinetochore
function (Howman, 2000; Blower and Karpen, 2001; Oegema et al.,
2001) by recruiting the inner kinetochore proteins CENPC, CENPN and
CENPB (Guse et al., 2011; Carroll et al., 2009; Ando et al., 2002). The
kinetochore interface consists of a large number of other centromere
proteins (CENPs) that form constitutive a centromere-associated
network (CCAN) (for overview see McKinley and Cheeseman and the
references therein) (McKinley and Cheeseman, 2016). CENPA is also
involved in response to DNA damage and ensures genome integrity
(Mathew et al., 2014; Lawrence et al., 2015). Several recent reports
implicateCENPA in numerous human cancers such as breast, liver, colon,
lung, blood, ovarian and pancreatic (Zhang et al., 2014; Habel et al.,
2013; Toh et al., 2011; Rajput et al., 2011;Huet al., 2010; Biermannet al.,
2007a; Biermann et al., 2007b; Furukawa et al., 2006; Li et al., 2007;
Tomonaga et al., 2003; Qiu et al., 2013). Increased expression of CENPA
gene correlates negatively with patient survival (Zhang et al., 2014;
Habel et al., 2013; Qiu et al., 2013). CENPA is also associated with the
transformation of lymphoblasts by Epstein–Barr virus (Dai et al., 2012).
Although the signiﬁcance of CENPA in human cancers has been
documented its relevance inGBMandGICs remains to bedemonstrated.
In this paper we investigated the expression of CENPA and several other
CENPs in GBM, brain tissues, GICs, NSCs, a neural fetal cells (NFCs) line,
induced pluripotent stem cells (iPS), dopaminergic neurons and many
other cell and tissue types using bioinformatics analysis. We also
investigated the effect of CENPA gene knock-down on sphere forming
ability, stemness and proliferation of GICs.
2. Materials and methods
2.1. Tissue specimens and cell culture
The study was approved by the Regional committee for medical
and health research ethics (REC South-East S-07321d). Biological
material and personal health data have been collected and used in
accordancewith informed consent from patients included in the study
and in compliance with the institutional guidelines pertaining to use
of such issued by the department of research support at Oslo
University Hospital. Tissue specimens were harvested from consent-
ing patients and were obtained as a part of surgical procedures for
treating GBM. Normal brain tissue was obtained from fresh human
temporal lobes surgically resected to treat medically refractory
epilepsy. All biopsy specimens were evaluated by neuropathologists.
Tumor biopsies underwent mechanical dissociation and
Trypsin-EDTA (Gibco, Life Technologies, NYC, NY, USA) was added
for enzymatic dissociation. Subsequently, 2 mg/ml human albumin
(Octapharma pharmazeutika produktionges, Vienna, Austria) was
used to block the Trypsin effect and the cells were washed in L-15
(Lonza, Basel, Switzerland) before being plated in serum-free neuro-
sphere medium containing 10 ng/ml basic ﬁbroblast growth factor
(bFGF) and 20 ng/ml epidermal growth factor (EGF) (both R&D Inc.,
Minneapolis, MN, USA), B27-supplement (1:50, Invitrogen, Carlsbad,
CA, USA), 100 U/ml Penicillin/streptomycin (Lonza), 1 ng/ml Heparin
(LeoPharma, Ballerup,Denmark) and8 mMHepes (Lonza) inDulbecco's
modiﬁed essential medium with nutrient mix F-12 and Glutamax
(DMEM/F12, Invitrogen). Dissociated GBM biopsies grown as free-
ﬂoating spheres in serum free-medium containing mitogens (EGF and
bFGF) are highly enriched for GICs. GIC culture T65 was previously
extensively characterized for stemness (CD133, CD44, SSEA-1/CD15,
CXCR4, CD9, CD166, A2B5) and tumor forming capability by transplant-
ing into the brain of SCID mice (Stangeland et al., 2015; Joel et al., 2015).
The cells were cultured in 75 cm2 non-treated ﬂasks (Nunc, Roskilde,
Denmark) at a density of 10⁵ cells/ml and supplemented with EGF andbFGF twice aweek.When the spheres reached approximately 100 μm in
diameter they were dissociated into single cells.
Tissue specimens from the adult human brain were dissociated
into single cells and cultured according to our FAILSAFE protocol (1%
FBS, 10 ng/ml bFGF and 20 ng/ml TGF α) that ensures robust
long-term propagation of multipotent stem cells from the adult
human brain (Murrell et al., 2013).
2.2. Microarray analysis and public database mining
Hierarchical clustering with distance matrix and the Principal
ComponentAnalysiswereperformedusing J-Express software (Molmine,
Bergen, Norway). For these analyses we used our microarray expression
data derived from GIC, neural fetal cells (NFCs), brain tissue and NSC
cultures with submission numbers GSE60705, GSE53800, GSE41470
(encompassing GSE41467, GSE41390, and GSE41394), as well as the
following publically available (GEO repository) microarrays encompass-
ing: additional sets of GICs (GSE36426), astrocytes (GSE47515), breast
cancer stem cells and cell lines (GSE34987, GSE36102), iPS (GSE43364,
GSE43903, GSE41565), GBM cell lines (GSE43452), iPS derived partially
differentiated neurons (GSE42265), NSCs (GSE32658), ESCs and ﬁbro-
blasts (GSE37077) and leukocytes (GSE42133).
For Fig. 2: The expression of eleven CENPs was analyzed in the
previously deﬁned subset of 200 GBM samples from TCGA (Verhaak et
al., 2010). PCA, HCA and HCA with distance matrix were performed
using J-express, Molmine, Bergen, Norway.
Fig. 1D and Supplemental Fig. 2: For PCA analysis we downloaded
the following subsets from GEO superseries GSE27869: GSM688128
(CENPA KD), GSM688129 (CENPB KD), GSM688130 (CENPC1 KD),
GSM688131 (CENPE KD), GSM688132 (CENPF KD), GSM688133
(CENPH KD). The above-mentioned microarrays were from GE
Healthcare microarray platform GPL4044 (spotted oligonucleotide,
CodeLink UniSet Human 20 K I Bioarray). Each culture featured only a
single CENP gene knockdown as speciﬁed. Bioinformatic analysis was
performed in J-Express.
For calculation of statistical parameters, we used Graphpad Prism
(www.graphpad.com).
2.3. Western blot and quantiﬁcation of protein expression
The cells were homogenized by triturating in Cell Extraction Buffer
(Mammalian cell extraction kit, Biovision, Milpitas, CA, USA) and
centrifuged through a QIAshredder (Qiagen, Venlo, Netherlands). 20–
40 μg of whole protein extract were mixed with loading buffer
(NuPAGE, Invitrogen) and loaded onto a 4–20% gradient Nu-PAGE gel
(Invitrogen). Protein gels were blotted onto 0.45 μm PVDF mem-
branes (Invitrogen) and western blots were performed as previously
described (Stangeland et al., 2015). For western blot we used
following primary antibodies: Anti-CENPA (#2186, rabbit, 1:1000),
Anti-ACTIN-B (#4967, rabbit, 1:1000) both from Cell Signaling
technologies (CST). The secondary antibody was ECL Anti-rabbit
IgG-HRP (NA934, 1:10000, Amersham). Protein quantiﬁcation was
performed as previously described (Stangeland et al., 2015). Brieﬂy,
CENPA and ACTB (actin) protein bands from the same lane were
quantiﬁed using densitometry function in Photoshop. ACTB was used
as a control for normalization. The Relative Protein Expression (RPE)
values were calculated by normalizing CENPA band intensities to
those of ACTB. The RPE values for KDs were then normalized to
non-silencing control and used for comparison.
2.4. RNAi-mediated gene knockdown
GIC culture T65 was used to establish stable CENPA knockdown
cultures KD1 (Clone ID V3LHS_403419), KD2 (V2LHS_150535), KD3
(V3LHS_313522), KD4 (V3LHS_403420) and a non-silencing (NS)
shRNA as a control (RHS4346) (all from Open Biosystems, Thermo
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9J. Behnan et al. / Neuroepigenetics 7 (2016) 6–18Scientiﬁc, Huntsville, AL, USA). Production of virus and transduction
were performed as previously described (Joel et al., 2015). The cellswere
selected on 1–3 μg/ml Puromycin (Sigma-Aldrich, St. Louis, MO, USA).
2.5. Cell viability and sphere forming assay
For analysis of cell viability we used a colorimetric test based on
tetrazolium salt — XTT (Roche Diagnostics, Indianapolis, IN, USA)
according to instructions from the manufacturer and previously
described procedure (Stangeland et al., 2015). P-values were
calculated using non-parametric Mann–Whitney test.
The sphere forming assay was done by seeding single cell
suspensions containing 500 cells per well in ultra-low attachment ﬂat
bottom 96-well plates for 10 days (Sarstedt). Subsequently, the plates
were imaged using GelCount™ (Oxford Optronics, Abington, UK). Only
spheres N50 μm were taken into consideration and 10 wells were
evaluated for each cell culture. The number and the size (average area)
of spheres were measured using software supplied by the manufac-
turers. All results were presented as a mean of ﬁve to six independent
experiments ± standard deviation. P-values were calculated using the
non-parametric Mann–Whitney test. Sphere volume was calculated
both by using themathematical formula V = (4/3)πr3 (shown in Fig. 7
and the Supplemental Fig. 4) and conﬁrmed using the sphere volume
function integrated in the Gelcount software (not shown).
2.6. Immunolabeling
GIC cultures were plated in 24-well plates (Sarstedt) or chamber
slides (Sigma-Aldrich) pretreated with Retronectin 50 μg/ml (Takara)
and incubated overnight to facilitate cell adhesion. Cells were ﬁxed
with 4% PFA andwashedwith PBS. Immunolabeling was performed as
previously described (Stangeland et al., 2015).
For detection of CENPA protein we used the primary antibody
Anti-CENPA [#2186, rabbit, 1:400, CST]. The secondary antibody was:
Alexa Fluor 594 A11012 (goat anti-rabbit, 1:500, Invitrogen).
2.7. Flow cytometry
Spheres from GSC culture T65 were dissociated into single cells, and
incubated overnight to recover. Cells were pelleted, and incubated with
primary antibodies against CD133/2-PE conjugated (Miltenyi biotec)
and SSEA1-PE conjugated (Becton-Dickinson). Cells were then ana-
lyzed using a LSRII ﬂow cytometer (Becton-Dickinson). We used the
following primary antibodies: Anti-Ki67 (ab16667, rabbit monoclonal,
Abcam) and Anti-SOX2 (MAB2018, mouse monoclonal, RD Systems).
3. Results
3.1. Expression of CENPA and other CENPs in GBMs, GICs, NSCs and
variety of human cell types
Expression of CENPA and the genes encoding other centromeric
proteins was assessed in a range of cell types, using our microarrays
and public data available in the GEO repository (Fig. 1 andFig. 1. Expression of CENP genes in GICs and a variety of other cell cultures. A. Hierarchic
predominantly undifferentiated (cluster 1) from partially differentiated (cluster 2) and diffe
BCC and other undifferentiated cells. Cell cultures demonstrating stepwise differentiation from
NFCs and a GBM tissue sample. Fully differentiated DA neurons (25 days of differentiation)
genes encoding CENPs in cluster 1. Hierarchical cluster analysis of cluster 1 from A revealed
GICs) and undifferentiated cancer cell cultures (GICs, BCCs and a few normal NSCs and ESC
samples uncovered two clusters according to CENPV expression. This analysis also showed th
to the left). D. Global analysis of selected genes encoding CENPs in human umbilical vein
CENPC1, CENPB, CENPE and CENPH. Using principal component analysis to compare gene e
between CENPA and CENPF knockdowns. For more information on differentially regulated gSupplemental Fig. 1). The expression of a variety of CENPs was
analyzed using hierarchical cluster analysis (Fig. 1). In addition to
GICs, NSC, GBM, commercial GBM cell lines and brain tissues we also
included the following: neural fetal cells (NFCs), astrocytes, iPS,
embryonic stem cells (ESCs), ﬁbroblasts, partially or fully differenti-
ated dopaminergic neurons, primary breast cancer cells (BCC) and
leucocytes (Fig. 1A, Supplemental Fig. 1). Our hierarchical cluster
analysis showed that genes encoding for CENPs are expressed inmany
cell types and tissues (Fig. 1A). While the whole group of genes
encoding for CENPs seems to be universally down-regulated in
leucocytes the gene CENPC1 was up-regulated (Fig. 1A). Using
principal component analysis (PCA) we compared the expression
proﬁles of genes encoding CENPs in the aforementioned set of cultures
and tissues. This analysis revealed that the majority of CENPs
exhibited similar proﬁles (Supplemental Fig. 1A–B) except for
CENPV, CENPF and CENPB that seem to be outliers (Supplemental
Fig. 1A–B). Hierarchical cluster analysis further separated all samples
into two categories (Fig. 1A). The ﬁrst category consisted of
undifferentiated and partially differentiated cell types while the
second category contained predominantly differentiated cells such as
fully differentiated dopaminergic neurons and leukocytes (Fig. 1A).
The “undifferentiated” category consisted of GICs, BCCs, GBM tissues,
GBM commercial cell lines, ESCs and NSCs. When only this category
was analyzed the samples were separated roughly to NSCs and cancer
stem/progenitor cell cultures (Fig. 1B). The “partially differentiated and
mixed” cell cultures group consisted of undifferentiated and partially
differentiated iPS, ﬁbroblasts, some GBM primary cell cultures and a
series of incompletely differentiated dopaminergic neurons (Fig. 1A).
By selecting the 17 most variable CENP-encoding genes in the GIC
cultures and commercial GBM cell lines we separated these cultures
into two clusters (Fig. 1C). Cultures in the ﬁrst and the second cluster
were characterized by relatively lowly and relatively highly expressed
CENPV respectively. Interestingly, GBM commercial lines were low in
CENPV. While the majority of the selected genes encoding CENPs were
typically highly expressed in the selected cultures there were several
cultures where the CENP genes were lowly expressed (Fig. 1C, red
dendrogram branches/lines on the left).
To further investigate the functional relationship between CENPA
and other CENPs we downloaded gene expression data from the study
where several hundreds of genes were knocked down (Fig. 1D and
Supplemental Fig. 2A–B) (Hurley et al., 2012). This data set contained
gene expression proﬁles of human umbilical vein endothelial cell
(HUVEC) cultures featuring single knockdowns (KDs) of CENPA,
CENPB, CENPC1, CENPE, CENPF and CENPH. Global analysis of gene
expression revealed that knockdowns of CENPA and CENPF lead to
similar gene expression proﬁles thus indicating a very close functional
relationship between these two CENPs (Fig. 1D). Furthermore, global
gene expression proﬁles of cell cultures featuring knockdowns of
CENPA, CENPF, CENPC1 and CENPB appeared to bear certain similarities
to one other (Supplemental Fig. 2A). Knockdowns of these four genes
all down-regulated the same set of genes while the knockdown of
CENPE and CENPH leads to the up-regulation of the same set
(Supplemental Fig. 2B). The set of genes, differentially regulated
between the two groups, encompassed genes involved in regulational cluster analysis of CENP gene expression performed on 134 microarrays separates
rentiated (cluster 3) cell cultures. The majority of NSC and GIC cultures clustered with
iPS to dopaminergic neurons in the course of 0–15 days clustered with iPS, ﬁbroblasts,
clustered with other fully differentiated DA neurons and leukocytes. B. Expression of
separation between normal undifferentiated cultures (encompassing NSCs and a few
s). C. Hierarchical cluster analysis of GIC cultures, GBM cell lines and three GBM tissue
at several GIC cultures had low CENPs expression (red branches on the dendogram tree
endothelial cell (HUVEC) cultures featuring single gene knockdowns of CENPA, CENPF,
xpression proﬁles of the knockdown cultures to one another we uncovered similarity
enes, 2D plots and statistical parameters for PCA see Supplemental Fig. 2.
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(Supplemental Fig. 2B).
3.2. Expression of CENPs in clinical GBM samples from TCGA
The Cancer Genome Atlas (TCGA) database comprises of large
amount of expressional data gathered from a vast number of cancer
tissues (http://cancergenome.nih.gov). The TCGA GBM tissue set was
previously described and divided into four putative GBM subtypes:
proneural, neural, mesenchymal and classical according to the
expression patterns of 840 identiﬁer genes (Verhaak et al., 2010).
The GBM subtypes all carried distinct mutations and had a
pronounced relevance in clinical settings. We analyzed the expression
of CENPA in clinical GBM samples from the TCGA database. The
expression of the CENPA gene was signiﬁcantly higher in proneural
tumors than in mesenchymal and classical tumors (Fig. 2A). Further,
we analyzed the expression of all genes encoding CENPs that were
present on the TCGA beadchip using PCA and cluster analysis. Global
analysis of the expression data for 200 GBM tissue samples from TCGA
(Verhaak et al., 2010) revealed similarities in expressions of CENPA,
CENPM, CENPN, CENPQ, CENPC1 and CENPT (Fig. 2B–C). PCA also
revealed that PC1, PC2 and PC3 identiﬁed CENPF, CENPB and CENPE as
outliers, respectively (Fig. 2B–C). We further tested if the genes
encoding CENPs were differentially regulated in GBM subtypes using
PCA. This analysis showed that the CENP gene expression patterns
clearly separated proneural and neural tumors from the mixture of
classical, mesenchymal and few neural samples (Fig. 2D). Curiously, the
unclassiﬁed TCGA GBM tissue samples (black) were not evenly spread
and congregated predominantly with the proneural or mesenchymal/
classical assemblies (Fig. 2D).
To analyze the co-expression of CENP genes we performed hierarchi-
cal cluster analysis on the same set fromTCGA (Verhaak et al., 2010). This
analysis revealedconsistentlyhighexpressionofCENPF in clinical samples
(Fig. 2E). CENPJ and CENPIwere lowly expressed in GBM tissues andwere
therefore excluded from someanalyses (Fig. 2E). The expression values of
CENPA clustered togetherwith CENPN, CENPE, CENPF and CENPM (Fig. 2E)
while CENPB, CENPI, CENPC1, CENPT, CENPQ and CENPJ clusteredwith one
another (Fig. 2E). The two gene clusters: CENP(AEFNM) andCENP(BCTQ)
were conﬁrmed using another clustering method (Fig. 2F). We further
tested if the expression of the two following gene signatures: a)
CENP(AEFNM)_HIGH/CENP(BCTQ)_LOW and b) CENP(AEFNM_LOW/
CENP(BCTQ)_HIGH had an impact on patient survival. When all GBM
tissue samples from the TCGA set (Verhaak et al., 2010)were tested there
was no signiﬁcant effect on patient survival (Supplemental Fig. 3A–B).
However,whenonly themesenchymal tissue sampleswere analyzed (Fig.
2G) the expression of the signature CENP(AEFNM)_HIGH/CEN-
P(BCTQ)_LOW correlated with signiﬁcantly worse survival (Fig. 2H).
3.3. Expression of CENPA protein in GICs
We have previously shown that CENPA was up-regulated in GIC
cultures and GBM tissues at mRNA and protein levels (Stangeland et
al., 2015). Here we evaluated the expression of CENPA in GICs usingFig. 2. Expression of CENP genes in glioblastoma tissue samples from TCGA. A. TCGA divided
(Verhaak et al., 2010). CENPA is signiﬁcantly up-regulated in the proneural GBM subtype. Ast
p = 0.0043 while “***” corresponds to p = 0.002. P values were calculated using a Mann–W
GBM TCGA. 2D plot of principal component analysis (PCA) showing separation of CENP ge
CENPs (CENPF, CENPB and CENPEwere outliers). The higher proximity of CENP genes in PCA in
B. D. PCA analysis of CENPs expression in subtypes of GBM from TCGA (same set as in A)
proneural (dark blue) and neural (light blue) subtypes could be separated from the rest of GB
from TCGA (Verhaak et al., 2010) with reference to the four subtypes. F. Hierarchical clusterin
distinct CENP clusters: CENP-A, N, E, F, andM vs. CENP-B, I, C1, T, Q, and J. G. Expression of the
patients indicated in blue (blue dendrogram branches) was plotted against the survival of pa
groups as shown by a Kaplan–Meier (KM) graph (H). The blue signature [highly expressed C
The red signature correlated with better survival. The p value was calculated using a log-ran
from TCGA in relation to CENP expression see Supplemental Fig. 3.immunolabeling with a CENPA speciﬁc antibody (Fig. 3). CENPA
protein was detected in the nuclei of GICs represented by a very
speciﬁc spotty pattern (Fig. 3B). The intensity of the signal was
varying from nucleus to nucleus and some nuclei distinguished
themselves by both very bright spotty CENPA staining and a “cloudy”
appearance in the surrounding nucleoplasm (Fig. 3E). This additional
staining could indicate ectopic assemblage of CENPA protein in the
peri-centromeric regions or along the chromosomes (neocentro-
meres). CENPA was otherwise expressed exclusively in the nuclei
where it overlapped (Fig. 3C and F) with DAPI staining (Fig. 3A and D).
Expression of CENPA in GICs during mitosis was followed using
immunolabeling (Figs. 3–4). During interphase the expression of
CENPA in GICs was nuclear and appeared typically either as spotty
patterns (Fig. 3B) or “spotty + cloudy” patterns (Fig. 3E). During
prophase the spotty pattern disappeared and was replaced by a
diffuse appearance (Fig. 3H). During the other phases of mitosis the
typical patterns disappeared and the CENPA protein could also be
detected in the cytoplasm (Fig. 4B, E, H and K). The characteristic
mitotic ﬁgures were documented using DAPI staining (Fig. 4A, D, G
and J).
3.4. CENPA gene knockdown in GIC cultures
To investigate the function of CENPA in GICs we performed
knockdown of this gene using RNAi technology. We utilized four
different shRNA constructs and a non-silencing (NS) control. To
assess the efﬁciency of CENPA gene knockdown we used qPCR
(not shown), western blot (Fig. 5A–B) and immunolabeling (Fig.
6). Quantiﬁcation of western blots showed that the levels of
CENPA were reduced by 20–70% in the knockdown cultures KD1,
KD2, KD3 and KD4 (Fig. 5A–C). The relative expression of CENPA
protein in knockdown cultures was also investigated using
immunolabeling. This analysis showed that the levels of CENPA
were reduced in nuclei of knockdown cultures (Fig. 6). In
conclusion, the immunolabeling showed signiﬁcant reduction in
CENPA protein levels in all four KD cultures (not shown for KD2).
The intensity of CENPA-speciﬁc signal was lowest in KD3 and KD4
(Fig. 6J and N). The GFP expression is presented in green (Fig. 6C,
G, K and O).
3.5. Knockdown of CENPA reduces stemness and sphere forming ability
of GICs
Knockdown of CENPA gene resulted in impaired growth of GIC
cultures grown as spheres (Figs. 5 and 7). GBM spheres featuring
CENPA KD were smaller in size (Fig. 5D and Supplemental Fig. 4A). To
test the expression of markers for stemness and cell proliferation we
performed ﬂow cytometry analysis. This analysis revealed reduced
levels of the cell proliferation marker Ki67 and the stemness marker
SOX2 in KD2, KD3, and KD4 cultures but not in the less efﬁcient KD1
culture (Fig. 5E). To investigate the degree of linear dependence
between the protein levels of CENPA and SOX2 and CENPA and Ki67
we compared the quantiﬁed western data to the FACS data usingall GBM clinical samples into four subtypes: proneural, classical, neural andmesenchymal
erisks correspond to p values and indicate levels of signiﬁcance. “**” here corresponds to
hitney non-parametric test. B. The expression of eleven CENPs in GBM samples from
nes according to their expression in GBM tissues from TCGA. PCA showed grouping of
dicates a higher level of co-expression in GBM samples. C. 3D plot of the PCA analysis in
. This analysis showed that CENPs are not randomly expressed in GBM subtypes. The
Ms according to CENP expression. E. Hierarchical cluster analysis of CENP genes in GBMs
g with distance matrix analysis of the same set as in E. Analyses in E and F revealed two
ninemost variably expressed CENPs inmesenchymal GBM samples. The survival of GBM
tients indicated in red. H. The survival of patients was signiﬁcantly different in the two
ENP(AEFM) and lowly expressed CENP(BCTQ)] correlated with shorter patient survival.
k (Mantel-Cox) test. For more information on KM graph of survival of all GBM patients
12 J. Behnan et al. / Neuroepigenetics 7 (2016) 6–18Pearson product–moment correlation coefﬁcient (PPMCCr) calcula-
tion. Correlation was excellent: r = 0.91 and r = 0.96 for CENPA/
SOX2 and CENPA/Ki67 levels respectively.
To assess cell growth of cell cultures featuring CENPA knockdown
we measured cell viability using XTT kit. Moderate but signiﬁcant
reduction in cell viability was observed in all cultures (Fig. 7A). In the
KD1 cell culture cell viability was assessed in subsequent passages up
to 80 days after transduction (Supplemental Fig. 4B). This culture
started showing reduced cell viability only gradually and after 72 days
in culture it was half as high as in the NS control (Supplemental Fig.
4B).
Sphere forming ability is usually considered as a retrospective
assay to estimate the number of tumor initiating cells. Spheres
featuring CENPA knockdown appeared smaller than the correspond-
ing “wild-type” spheres (Fig. 5D). To quantify the effect of CENPA KD
on sphere forming ability we performed a sphere forming assay (SFA)
(Fig. 7B–D and Supplemental Fig. 4C–D). SFA assays performed in all
four cultures showed reduced sphere forming abilities. While the
average diameter of spheres in NS was 94.93 ± 12.16 μm, the
diameter of spheres featuring CENPA knockdown was reduced to
81.26 ± 9.08 μm, 74.80 ± 10.18 μm, 80.88 ± 13.75 μm and
86.50 ± 18.63 μm in KD1, KD2, KD3 and KD4 respectively (Fig. 7B).
The average number of spheres in NS was 47.13 ± 8.72 (Fig. 7C). This
number was signiﬁcantly reduced in the knockdown cultures: KD1
(27.97 ± 48.73), KD2 (26.80 ± 11.78), KD3 (25.07 ± 7.34) and KD4
(28 ± 12.05) (Fig. 7C). The total sphere volume per well (TSVPW)
was dramatically reduced in all tested knockdown cultures (Fig. 7D).
While the average TSVPW in the NS culture was 2,261e7 ±
1,088e7 μm3, we calculated the average TSVPW of 8,656e6 ±
5,150e6 μm3, 5,929e6 ± 2,909e6 μm3, and 7,448e6 ± 3,521e6 μm3,
1,075e7 ± 0,689e7 μm3 in KD1, KD2, KD3 and KD4 respectively (Fig.
7D).Fig. 3. Expression and localization of CENPA protein in GICs. A–F. Two cells showing typica
shown. DAPI staining is shown in A, D and G. Immunolabeling with Anti-CENPA antibody iIn one culture (KD1) we assessed the effect of CENPA KD on sphere
forming ability also on days 42 (Supplemental Fig. 4C), 56 (not
shown) and 73 (Supplemental Fig. 4D) after transduction (as outlined
in Supplemental Fig. 4B). The parameters of the SFA in KD1 were
signiﬁcantly reduced after 42 days in this culture and the difference
became even more prominent after 72 days (Supplemental Fig. 4C–
D). Other cultures (KD2, KD3 and KD4) showed only small
ﬂuctuations after prolonged incubation.
To calculate the degree of linear dependence between the
knockdown efﬁciencies and the results of the functional assays we
used again the Pearson product–moment correlation coefﬁcient
(PPMCCr) calculation. Correlations between the average number of
spheres and knockdown efﬁciency and the sphere diameter (median)
and knockdown efﬁciency were r = 0.67 and r = 0.81 respectively.
Correlations between the average cell viability and knockdown
efﬁciency and the average volume of spheres (per well) and
knockdown efﬁciency were r = 0.43 and r = 0.56 respectively. In
conclusion, while the size and number of the spheres correlated nicely
to the CENPA knockdown efﬁciency (at the protein level) the cell
growth parameters, such as cell viability and sphere volume (TVSPW)
showed moderate correlation.
4. Discussion
Uncontrolled cell division is a hallmark of all cancers, including
glioblastoma. Consequently, several therapeutics that speciﬁcally
target mitosis have been designed and tested in clinical settings
(Dominguez-Brauer et al., 2015; Rath and Kozielski, 2012; De Witt
Hamer et al., 2011; Herman et al., 2015; Kaneta and Ullrich, 2013;
Lim et al., 2014; Sarcar et al., 2011; Chung et al., 2012). CENPA is a
centromere-associated variant of histone H3 that plays an important
role during cell division by ensuring proper separation of the sisterl (A–C) and strong (D–F) staining of CENPA. G–I. A typical prophase staining in GICs is
s shown in B, E and H. Merge of the two is shown in C, F and I.
13J. Behnan et al. / Neuroepigenetics 7 (2016) 6–18chromatids. It is frequently up-regulated in cancers (Zhang et al.,
2014; Habel et al., 2013; Toh et al., 2011; Rajput et al., 2011; Hu et al.,
2010; Biermann et al., 2007a; Biermann et al., 2007b; Furukawa et
al., 2006; Li et al., 2007; Tomonaga et al., 2003; Qiu et al., 2013) and
has been suggested as a potential therapeutic target (Stangeland et
al., 2015; Li et al., 2011). A study in hepatocellular carcinoma
revealed that CENPA was highly up-regulated at mRNA and protein
levels in this cancer (Li et al., 2007; Li et al., 2011). Knockdown of
CENPA signiﬁcantly decreased proliferation of hepatocellular carci-
noma cell lines and reduced tumorigenic features in vivo (Li et al.,
2011).
We have recently identiﬁed a CENPA containing co-expression
module highly up-regulated in glioblastoma tissue samples and GICs
(Stangeland et al., 2015). Among the nine genes, CENPAwas the most
up-regulated one (Stangeland et al., 2015). Genes that show similar
expression patterns might be functionally related. It was therefore not
so surprising that these genes encoded proteins that were all part of
the same functional network (Stangeland et al., 2015).Fig. 4. Expression and localization of CENPA protein in GICs during cell division. A–F. Typ
telophase staining. DAPI staining is shown in A, D and G and J. Immunolabeling with Anti-CAssociation of CENPA with stemness and highly proliferative state
was also observed in normal mammal cells (McGregor et al., 2014;
Ambartsumyan et al., 2010). In cardiac progenitors CENPA is not only
highly up-regulated but its expression is also increased in the embryonic
heart and down-regulated in the adult heart and upon differentiation
(McGregor et al., 2014). Knockdown of CENPA in cardiac progenitors
slowed down cell proliferation (McGregor et al., 2014). Our current
study in GICs was in agreement with these results. We performed
several tests to determine inﬂuence of CENPA knockdown on stemness
of GICs. The number of spheres retrospectively indicates the number of
GICs in the culture. Our study shows that the knockdown of CENPA gene
severely impaired sphere formation by decreasing all three major
parameters: number, diameter and volume of the spheres. However,
only the number of spheres would suggest reduction in the population
of GICs. The diameter and especially total volume of the spheres
(TVSPW) are more related to cell growth (cell biomass) and
proliferative capability as we previously reported (Stangeland et al.,
2015; Joel et al., 2015; Mughal et al., 2015).ical metaphase staining. G–I. Typical anaphase staining in GICs is shown. J–L. Typical
ENPA antibody is shown in B, E, H and K. Merge of the two is shown in C, F, I and L.
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14 J. Behnan et al. / Neuroepigenetics 7 (2016) 6–18In the present study we show that CENPA knockdown not only
reduced the stemness of the GICs but also the cell viability, although
the effect was rather mild. The results of the functional essays (SFA
and cell viability) were further conﬁrmed by assessing SOX2 and Ki67
expression. We detected a decrease in the expression of the stem cellmarker SOX2 in CENPA knockdown cultures. The decrease in CENPA
protein levels was also nicely paralleled by decrease in proliferation
marker Ki67 levels. This was in agreement with another knockdown
study where decrement in CENPA expression correlated with
decreased Ki67 expression [56].
Fig. 6. Conﬁrmation of knockdown by immunolabeling. Typical CENPA staining in non-silencing (A–D), KD1 (E–H), KD3 (I–L) and KD4 (M–P) cultures. DAPI staining is shown in A, E,
I and M. Immunolabeling with Anti-CENPA antibody is shown in B, F, J and N. GFP is shown in C, G, K and O. Merge of the two is shown in D, H, L and P.
15J. Behnan et al. / Neuroepigenetics 7 (2016) 6–18Although the complete loss of CENPA led to genomic instability
and embryo lethality in mouse (Howman et al., 2000) it has been
shown that colorectal cancer cells can sustain some centromere
function and assembly of kinetochore proteins even with as little as
1% of residual CENPA protein (Fachinetti et al., 2013). Furthermore,
the knockdown of CENPA in ﬁbroblasts and iPS showed that the latter
tolerated much better depletion of this gene (Ambartsumyan et al.,
2010). While ﬁbroblasts featuring CENPA knockdown could not
sustain functional centromeric mark the iPS could (Ambartsumyan
et al., 2010). The abovementioned examples from the literature could
explain why the proliferation of our CENPA knockdown cultures was
only mildly affected in spite of very good CENPA knockdown efﬁciency
and reduction in Ki67 levels. In conclusion, our study shows that CENPA
regulates stemness of GICswhile the effect of this gene on cell proliferation is
less evident.
Although CENPA protein is typically afﬁliated with centromeres its
presence at active promoters has also been reported (Cole et al.,
2011). Frequently, this CENPA is quickly targeted for degradation
(Hewawasam et al., 2010; Ranjitkar, 2010). Abnormally increased
CENPA expression, that is very often detected in human cancers,
typically results in centromere expansion (Tomonaga et al., 2003). Insome cases CENPA nucleosomes can be detected in non-centromeric
regions where the protein might lead to changes in gene regulation
and chromosome fragility (Lam et al., 2006). Furthermore it has been
shown that CENPA can be recruited by artiﬁcially induced DNA brakes
in osteosarcoma studies (Zeitlin et al., 2009). This phenomenon seems
to be mediated by uracil DNA N-glycosylase (Zeitlin et al., 2011). Some,
so called, CENPAhotspots accumulate in chromosome telomeric regions
such as region 8q24/Myc which is associated with genome instability
(Athwal et al., 2015). This particular region has been shown to inﬂuence
glioma risk (Enciso-Mora et al., 2013). Our study showed that CENPA
was especially highly up-regulated in proneural GBM samples. Each of
the four GBM subtypes is deﬁned with a speciﬁc set of expressed genes,
genetic aberrations and epigenetic marks (Verhaak et al., 2010). It
remains to be revealed why this particular subtype is associated with
highest CENPA expression and if the eventual CENPA hotspot would be
involved in this.
A comprehensive bioinformatic analysis of CENPs as a group has
never been done. Neither has the role of CENPs in regulation of
stemness been determined. In our study we included a large set of
stem, progenitor and differentiated cells (Fig. 1). Although, we
focused especially on GICs this analysis revealed interesting
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16 J. Behnan et al. / Neuroepigenetics 7 (2016) 6–18information of CENPs' speciﬁc expression in differentiated cells and
some tissues that we otherwise included only as controls (Fig. 1). For
example CENPI and CENPH were relatively lowly expressed while
none of the CENPs was universally expressed in all tested cell cultures.
CENPC1 and CENPV were speciﬁcally expressed in mature normal
lymphocytes (Fig. 1A) and dopaminergic neurons (DNs), respectively.
The latter was expressed both in DNs fully and those partially
differentiated from iPS and in a few GIC cultures. CENPF was highly
up-regulated only in partially differentiated DNs and otherwise in
stem and progenitor cells, GBM, GICs and other breast cancer cells. All
other CENPs were predominantly up-regulated in undifferentiated
and partially differentiated cells and down-regulated in differentiated
cells. Further reﬁnement revealed that among the undifferentiated
cells normal NSCs had slightly different proﬁles than the cancer cells
and ESCs (Fig. 1B). The analysis of the entire CENP proﬁle in a number
of cell types also revealed that undifferentiated and differentiated
cells have quite distinct CENP proﬁles (Fig. 1A).
Within the CCAN all CENPs can be divided in ﬁve groups (McKinley
and Cheeseman, 2016): 1) CENP(C), 2) CENP(LN), 3) CENP(HIKM), 4)
CENP(OPQUR) and 5) CENP(TWSX). The expression patterns of
selected CENPs in undifferentiated cells (Fig. 1B) seem to beappropriately reﬂecting these functional groups. Out of 10 CENPs
present on the bead chip (U/R/T/W/S and W were absent) nine were
grouped as in CCAN (underlined). Firstly, CENPC showed an
expression pattern quite different from the rest of the CENPs and
formed its own group (Fig. 1A). Secondly, L and N are in the same
cluster while K, M and I clustered together. H clustered with L and N
andwas thus the only CENP outlier in this analysis. For all other CENPs
the expression patterns at the mRNA level (hierarchical cluster
analysis) reﬂected functionality in the CCAN complex.
CENPs do not seem to be randomly expressed in subtypes of GBM
tissues in TCGA (Fig. 2D). Proneural and neural groups exhibited CENP
proﬁles quite distinct from the rest of tissues that belonged to classical
andmesenchymal subgroups or were “unsorted” (black spheres in Fig.
2D). Furthermore the two CENP signatures that we identiﬁed (Fig. 2F–
G) correlated with very different patient survival (Fig. 2H). Worse
survival correlated with highly expressed CENPs: A, E, F, N andM. Best
survival was obtained if these ﬁve CENPs were down-regulated
(although CENPs B, C, T and Q were up-regulated). Genes with similar
expression patterns might be functionally related. In predominantly
undifferentiated cells CENPA was co-expressed with CENPB, CENPN,
CNEPL and CENPH (Fig. 1B). CENPN and CENPB are clearly very closely
17J. Behnan et al. / Neuroepigenetics 7 (2016) 6–18functionally related with CENPA as they are both inner kinetochore
proteins (with CENPC) and directly recruited by CENPA (Guse et al.,
2011; Carroll et al., 2009; Ando et al., 2002). We previously showed
that CENPF was highly up-regulated in GICs (Sandberg et al., 2013).
Both in GICs and in GBM tissues CENPA, CENPE and CENPF were the
part of the same network (Sandberg et al., 2013; Stangeland et al.,
2015). A recent study showed that targeted disruption of PTEN leads
to neoplastic transformation of human NSCs (Duan et al., 2015). The
reprogramming of NSCs towards a glioblastoma stem cell-like
phenotype by PTEN KD leads also to up-regulation of CENPA, CENPE
and CENPF (Duan et al., 2015). In the current communication we show
that several CENPs including these three genes (Fig. 1A) show similar
expression patterns. Both CENPF and CENPE are required for the
proper function of the kinetochore (Feng et al., 2006; Schaar et al.,
1997; Yen et al., 1992). CENPF is also implicated in other cancers such
as esophageal squamous cell carcinoma (Pimkhaokham et al., 2000).
Is has been suggested as a therapeutic target and has been extensively
targeted with a speciﬁc inhibitor GSK923295 (Wood et al., 2010).
Inhibition of CENPE induced tumor cell apoptosis and tumor
regression and caused aneuploidy (Bennett et al., 2015). Our
bioinformatics analysis also showed that knockdowns of CENPA and
CENPF resulted in similar downstream effects (Fig. 1D). Taking into
account that roles of CENPA, CENPE and CENPF in GICs are so
intertwined, targeting all three simultaneously could be an interesting
strategy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nepig.2016.08.002.
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